Shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) dropped 3.2% during mid-day trading on Wednesday . The stock traded as low as $1.20 and last traded at $1.21. Approximately 1,173,807 shares changed hands during mid-day trading, a decline of 20% from the average daily volume of 1,464,921 shares. The stock had previously closed at $1.25.
Analyst Ratings Changes
GOSS has been the subject of several analyst reports. Wedbush reaffirmed an "outperform" rating and set a $4.00 price objective on shares of Gossamer Bio in a research note on Friday, May 16th. The Goldman Sachs Group upped their price target on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, May 16th. Finally, HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday, March 18th.
Get Our Latest Analysis on Gossamer Bio
Gossamer Bio Stock Up 1.2%
The company has a quick ratio of 5.71, a current ratio of 5.71 and a debt-to-equity ratio of 6.70. The stock has a market capitalization of $278.44 million, a PE ratio of -5.33 and a beta of 1.86. The firm's fifty day moving average is $1.18 and its 200-day moving average is $1.10.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. Gossamer Bio had a negative return on equity of 128.98% and a negative net margin of 41.12%. The company had revenue of $9.89 million for the quarter, compared to analysts' expectations of $3.95 million. On average, equities research analysts predict that Gossamer Bio, Inc. will post -0.28 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the stock. Graham Capital Management L.P. purchased a new position in Gossamer Bio in the 4th quarter valued at approximately $32,000. Virtu Financial LLC acquired a new stake in Gossamer Bio in the first quarter valued at $38,000. Invesco Ltd. purchased a new position in shares of Gossamer Bio in the first quarter valued at $48,000. Fullcircle Wealth LLC purchased a new position in shares of Gossamer Bio in the fourth quarter valued at $43,000. Finally, Velan Capital Investment Management LP acquired a new position in shares of Gossamer Bio during the 4th quarter worth $68,000. 81.23% of the stock is owned by hedge funds and other institutional investors.
Gossamer Bio Company Profile
(
Get Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Read More
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
